Biglycan production is altered by iloprost in fibroblasts from control subjects but not from COPD patients. Biglycan production in distal lung fibroblasts from control subjects (n = 7; A) and patients with COPD (n = 7; B). Cells were stimulated with iloprost (10, 100 or 1000 nM) and in combination with TGF-β1 (10 ng/ml) in 0.4% fibroblast medium pretreated with indomethacin (3 μM). Changes in biglycan production after TGF-β1 stimulation are expressed as fold change compared to non-stimulated fibroblasts in 0.4% medium from control subjects (C) and COPD patients (D). Data are presented as median with individual values and median values are represented as a line. *p < 0.05; **p < 0.01. #p < 0.05 and ##p < 0.01 indicate significant differences in biglycan production after TGF-β1 stimulation compared to basal levels. $p < 0.05 indicate significant difference in biglycan synthesis after TGF-β1 stimulation between control and COPD fibroblasts. Statistical analysis is performed with ANOVA on ranks followed by a post hoc test to compare differences between control and COPD fibroblasts and within the control and COPD fibroblasts after iloprost and TGF-β1 stimulation.